The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Clinical outcomes of patients with AL amyloidosis with acquired factor X deficiency
Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, discusses a retrospective study investigating the rate of acquired factor X deficiency, a rare complication of light chain (AL) amyloidosis. The study revealed that 4.4% of patients with AL amyloidosis in the database had factor X levels below 50%, with significant bleeding complications occurring in approximately 55% of these patients. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
The last abstract that I would like to mention is a poster presentation from our group on acquired factor X deficiency, a rare complication of AL amyloidosis. And in this, this is a retrospective study from our database of 1,956 patients with AL amyloidosis who underwent systematic screening of factor X levels. About 4.4% or 88 patients were diagnosed with factor X levels of less than 50%...
The last abstract that I would like to mention is a poster presentation from our group on acquired factor X deficiency, a rare complication of AL amyloidosis. And in this, this is a retrospective study from our database of 1,956 patients with AL amyloidosis who underwent systematic screening of factor X levels. About 4.4% or 88 patients were diagnosed with factor X levels of less than 50%. The median factor X level was 39% and the bleeding complications did not really occur in about 45% of patients. However, the rest of the patients did have some bleeding complications. Majority were mucocutaneous bleeding but about 16% did have GI bleeding and 9% had post-procedural bleeding.
Hematologic CR achievement for the underlying plasma cell dyscrasia clone did lead to improvement in factor X deficiency or tear factor X levels and the median improvement of greater than 50% did occur in 75% of patients following treatment and this was irrespective of what type of treatment was used.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Proclara, Caelum, Abbvie, Janssen, Regeneron, Protego, Pharmatrace, Telix, Prothena, AstraZeneca, Nexcella: Membership on an entity’s Board of Directors or advisory committees; Pfizer, Janssen, Attralus, GateBio, Abbvie, BridgeBio: Consultancy; Celgene, Millennium-Takeda, Janssen, Prothena, Sorrento, Karyopharm, Oncopeptide, Caelum, Alexion: Research Funding.
